1. P583 Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study. (27th May 2021) Authors: Mocci, G; Cuomo, A; Allegretta, L; Aragona, G; Colucci, R; Della Valle, N; Ferronato, A; Forti, G; Gaiani, F; Graziani, M G; Lorenzetti, R; Luzza, F; Penna, A; Pica, R; Piergallini, S; Rodinò, S; Scarcelli, A; Zampaletta, C; Cicerone, C; Cocco, A Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S536 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗